Hypothermic Cardiopulmonary Bypass (CPB) Model

Indication and Application:

Preclinical safety and efficacy validation of structural heart and perfusion medical devices (e.g., membrane oxygenators, arterial filters, CPB tubing coatings, centrifugal blood pumps, cardioplegia delivery systems), screening of pharmacological compounds targeting systemic inflammatory response syndrome (SIRS), and optimization of organ preservation strategies during deep hypothermic circulatory arrest.

Modeling Method:

• Large Animal Full-Scale CPB (Ovine/Porcine): Under general anesthesia and mechanical ventilation, advanced surgical access is established. Systemic anticoagulation is achieved using calibrated heparin administration (monitored via Activated Clotting Time / ACT greater than 400 seconds). Arterial cannulation is performed via the carotid artery or ascending aorta, and venous cannulation is secured via the jugular vein or venae cavae. The circuit is initiated, systemic core temperature is lowered via the heat exchanger (typically to mild 32C, moderate 28C, or deep hypothermia less than 18C), followed by cross-clamping of the aorta and delivery of cold crystalloid/blood cardioplegia to achieve cardiac arrest. After a designated bypass period, the animal is rewarmed, weaned from CPB, and protamine is administered for heparin reversal.

• Small Animal Miniature CPB (Rats): A specialized, ultra-low priming volume circuit is connected via tail artery/femoral artery cannulation and right atrial cannulation to simulate CPB hemodynamics on a rodent scale.

Clinical Relevance:

• Absolute Pathological Mimicry: The model perfectly captures the unique clinical challenges of CPB, including blood-biomaterial surface contact activation, shear-stress induced hemolysis, ischemia-reperfusion injury of the arrested myocardium, and hypothermia-induced coagulopathy.

• Gold Standard for Regulatory Device Submissions: Ovine (sheep) models are globally recognized by regulatory bodies (such as FDA and CE) as the gold standard for testing blood-contacting extracorporeal devices due to the high similarity of sheep coagulation cascades, hematological profiles, and vascular dimensions to human anatomy.

Key Evaluation Endpoints:

1. In Vivo / Surgical / Hemocompatibility Monitoring:

• Continuous Hemodynamic & Metabolic Tracking: Monitoring of mean arterial pressure (MAP), central venous pressure (CVP), pump flow rate, core temperature (nasopharyngeal and rectal), and frequent arterial blood gas (ABG) profiling (electrolytes, lactate, pH, pO2, pCO2).

• Anticoagulation & Hemolysis Metrics: Longitudinal evaluation of Activated Clotting Time (ACT), plasma free hemoglobin (fHb) to calculate the Normalized Index of Hemolysis (NIH), platelet count, and fibrinogen levels.

• Echocardiography & Intravascular Pressure: Assessment of Left Ventricular Ejection Fraction (LVEF) and myocardial contractility recovery kinetics during the post-bypass weaning phase.

2. Histopathology & Target Organ Damage Profile:

• Myocardial Tissue Assessment: H&E and Masson's Trichrome staining to evaluate subendocardial ischemia, contraction band necrosis, and edema.

• Pulmonary Injury Scoring (CPB-induced Acute Lung Injury): Quantitation of alveolar congestion, neutrophil infiltration, and alveolar wall thickening.

• Neurohistopathology (For DHCA Models): Nissl staining and TUNEL assay of the cerebral cortex and hippocampus to quantify ischemic neuronal degeneration and apoptosis.

• Renal Morbidity Profiling: Assessment of acute tubular necrosis (ATN) and glomerular congestion via specialized histomorphometry.

3. Molecular & Systemic Inflammatory Markers:

• Inflammatory Cascade Quantification: Longitudinal monitoring of systemic cytokine release (IL-6, IL-8, TNF-alpha, IL-1beta) via ELISA to evaluate circuit biocompatibility or drug efficacy.

• Endothelial Activation Markers: Expression analysis of von Willebrand factor (vWF), ICAM-1, and VCAM-1 in target organs via Immunohistochemistry (IHC).